Cargando…
Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with high-risk non-muscle invasive bladder cancer
INTRODUCTION: The initial treatment for high-risk non-muscle invasive bladder cancer (NMIBC) is endoscopic resection of the tumour followed by BCG therapy. In those who develop recurrence, the standard treatment is radical cystectomy. Despite the advancement in surgical technique and postoperative c...
Autores principales: | Jamil, Marcus L, Deebajah, Mustafa, Sood, Akshay, Robinson, Kathy, Rao, Krishna, Sana, Sherjeel, Alanee, Shaheen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661574/ https://www.ncbi.nlm.nih.gov/pubmed/31320352 http://dx.doi.org/10.1136/bmjopen-2018-028287 |
Ejemplares similares
-
Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study
por: Jamil, Marcus L, et al.
Publicado: (2019) -
The Management of Bacillus Calmette-Guérin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article
por: Kodera, Ahmed, et al.
Publicado: (2023) -
Vertebral Osteomyelitis Secondary to Bacillus Calmette-Guérin Instillation Therapy for Transitional Cell Carcinoma In Situ
por: Jaber, Tariq M, et al.
Publicado: (2021) -
Lumbosacral Vertebral Osteomyelitis With Iliopsoas and Epidural Abscess Following Intravesical Bacillus Calmette-Guérin Therapy
por: Abbas, Anas M, et al.
Publicado: (2023) -
Systemic Bacillus Calmette-Guérin (BCG) Infection With Renal Involvement: A Rare Complication of BCG Immunotherapy
por: Afonso, Raquel, et al.
Publicado: (2022)